PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: Trevigen, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Trevigen Launches Pharmacodynamic PAR ELISA Assay - Trevigen introduces a highly sensitive, quantitative and validated assay to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening
Trevigen Launches Pharmacodynamic PAR ELISA Assay

 

NewswireToday - /newswire/ - Arlington, VA, United States, 2008/10/08 - Trevigen introduces a highly sensitive, quantitative and validated assay to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Pharmacodynamic (PD) assays have recently been developed and employed early in the drug development process to assess the ability of potential drug candidates to hit their molecular target(s). These assays have the advantages of allowing molecular "proof of concept" investigations at an early stage development such as phase 0 trials. These assays also provide the opportunity to prospectively identify patients likely to respond in clinical trials.

In cancer drug development, a current molecular target of high interest is poly(ADP-ribose) polymerase-1 (PARP-1). The metabolism initiated by PARP-1 is fundamentally related to the recovery or death of cancer cells. PARP inhibitors are of particular interest in that they are very well tolerated but are selectively toxic to cancer cells deficient in homologous recombination (HR), which includes BRCA1/2 deficient breast cancer cells genetically defective in HR. Until now, the effectiveness of PARP inhibitors in cells and tissues have been difficult to assess. Trevigen solves this problem with the release of the Pharmacodynamic PAR ELISA Assay, which measures the in vivo end product of the PARP reaction called poly(ADP-ribose) or PAR. This high throughput, chemiluminescent assay kit has been validated on human peripheral blood lymphocytes and has also been shown to work with normal and tumor tissue. Using highly characterized antibodies in a sandwich ELISA format, the kit detects PAR down to 5 pg per ml. By determining PAR levels in vivo prior to and following administration of PARP inhibitors, the assay is ideal for determining the effectiveness of PARP inhibitors in many formats including in patients in clinical trials.

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.

Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and PARP antibodies. Visit our website or contact us at 1-800-873-8443 for more information.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Trevigen, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Trevigen Launches Pharmacodynamic PAR ELISA Assay

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Trevigen |
Publisher Contact: Shamain Dang - Trevigen.com 
1-800-873-8443 info[.]trevigen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Trevigen, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Trevigen, Inc. / Company Profile


Read Research Most Recent Related Newswires:

DSM-Niaga Ready for Commercial Scale Production of 100%-recyclable Carpets
DSM Dyneema Introduces Whole New Level of Cut Protection with Black Dyneema® Diamond Technology
DSM Presents Sustainable and Healthy Dairy Solutions At FoodTech 2016
Frost & Sullivan Highlights GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
DSM to Present its Latest Advances in Skin Biochemistry At IFSCC Conference
DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant
DSM Dyneema Successfully Defends Key Patent Against Competitor Challenge
DSM Expands its Automotive Electronics Portfolio with High-flow Akulon PA66
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions
BD Announces New Software Release for Pyxis Enterprise Solution
DSM Opens its Asia Pacific Personal Care Technical & Application Center in Shanghai

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)